Editor's note: The topic of testosterone (T) and prostate cancer is timely and provocative. The Institute of Medicine report on testosterone and aging suggested that knowledge regarding T-replacement therapy in aging men was inadequate, urging a cautious approach to T replacement in this population. Prostate cancer is a disease that is highly prevalent and potentially lethal. The initiation and progression of prostate cancer have been linked to complex hormone-related mechanisms. These findings have led many researchers to question whether the administration of exogenous testosterone might be a highly relevant risk factor for prostate cancer, affecting both its pathogenesis and natural history. The fact that men undergo a slow but steady decline in their total and bioavailable testosterone levels between the ages of 25 and 75 y-a concept known as Aging Male Syndrome (AMS)-is becoming more widely recognized. This age-related decrease in serum testosterone levels is known to be due to primary testicular changes and to altered neuroendocrine regulation of Leydig cell function. These changes coincide with an increase in the incidence of prostate cancer with aging. However, older men with established low serum testosterone levels have become increasingly interested in the use of testosterone replacement therapy (TRT). In addition to having a beneficial effect on sexual performance, TRT has also been shown to improve the overall quality of life in aging hypogonadal men. These positive changes include increases in lean body mass, bone mineral density (BMD), and muscle strength and improvement in mood. Therefore, any potential connection between TRT and prostate cancer risk is of concern. A review of some of the potentially important factors involved in the complex relationship between prostate cancer risk and TRT should be of value.
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Any discussion of prostate cancer risk must first recognize the fact that prostate cancer is a slow growing disease, with the initial malignant transformation occurring much earlier than its clinical demonstration. Furthermore, cadaver studies have indicated a high incidence of clinically insignificant prostate cancer in patients who were not diagnosed with prostate cancer and who died from other causes, including old age. The extended natural history of this disease represents a significant dilemma for researchers seeking to identify the effect of testosterone levels early in a man's life on the proposed promotional effect of testosterone and its derivatives on prostate cancer cells. Moreover, several factors can alter the effect of testosterone, including the relative ratios of free testosterone and estrogen to total testosterone levels and changes in intraprostatic versus serum levels of testosterone. The fact that testosterone is an essential growth factor for normal prostate cell differentiation and growth has been well established. Many researchers have reported a significant correlation between prostate gland size and the level of dihydrotestosterone (DHT) in the prostate. Testosterone levels also play a pivotal role in the differentiation and maintenance of selected prostate cancer cells lines both in vitro and in vivo, as seen in the temporary therapeutic effect of hormonal blockade in patients with clinically relevant prostate cancer. In spite of the fact that this effect appears to be altered later in life, several studies have demonstrated that a low testosterone level prior to treatment is an independent predictor of a more aggressive, higher grade tumor, an increased likelihood of extraprostatic disease at the time of diagnosis, and a worse treatment response. In a sense, these findings indicate a protective effect of 'normal' testosterone levels on the natural history of prostate cancer. Conversely, some studies have failed to find a correlation between testosterone levels and tumor stage or prostate-specific antigen (PSA) levels, while other studies have reported an increase in tumor relapse rates after the treatment was associated with high testosterone levels. It is interesting to note that although PSA levels have been reported to have a significant relationship with prostate volume and growth, they did not correlate with testosterone levels in patients diagnosed with prostate cancer. This finding may indicate that testosterone's growth-promoting effect on malignant prostate cells differs from its effect on benign cells.
Several other observations are worthy of consideration in assessing the risk of prostate cancer associated with TRT. Based on the observation that tissue concentrations of testosterone and DHT are substantially higher in the prostate than in serum, androgen supplementation may cause modest increases in serum androgens while having little effect on intraprostatic androgen levels. Furthermore, the increase in serum concentrations to 'super-normal' levels due to testosterone supplementation and the downstream products of testosterone metabolism may hold the key to its effect on prostate cancer risk. The effects of other hormones and growth factors may be crucial in determining the magnitude of the risk associated with TRT. These somewhat contradictory observations from the literature may indicate that while the effect of normal levels of testosterone and its derivatives on prostate cancer is protective, both hypogonadal and hypergonadal situations may exist, similar to the pathological effect of other hormones. At this time, the term hypergonadism has not been established in the literature. Further studies are needed to determine an age-related physiological range for testosterone levels that would be similar to such ranges for growth hormone and thyroid hormone.
In conclusion, despite the theoretical increased risk of prostate cancer following TRT, there is currently no evidence that a de novo or pre-existing prostatic malignancy can be initiated and promoted by administration of testosterone in hypogonadal men. In fact, a protective role of normal levels of testosterone on the natural history of prostate cancer is highly possible. Many studies have demonstrated that a low pretreatment testosterone level can predict prostate cancers that are more likely to be aggressive, high-grade tumors with a greater likelihood of having metastasized by the time they are diagnosed and a lower likelihood of responding favorably to treatment. Therefore, until the true risk of prostate cancer associated with TRT is documented in long-term studies, it is not only clinically crucial but ethically important to establish careful guidelines for screening occult prostate cancer prior to hormone therapy. Careful monitoring should be in place for all considering androgen therapy. These measures include serum levels of testosterone, PSA, hemoglobin, and hematocrit, and a digital rectal examination every 3 months in the first year and semiannually thereafter.
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